Fenbendazole is a broad-spectrum benzimidazole anthelmintic. It is widely used for animals, including mammals, fish, reptiles, birds, and freshwater shrimp tanks, to treat parasitic diseases and worms. Several animal studies indicate that fenbendazole can also have anti-tumor effects. It can reduce the number of tumor cells and their sensitivity to chemotherapy, making it a potential cancer treatment for humans.
A recent study found that fenbendazole is effective in a variety of mouse models of cancer, including those resistant to paclitaxel. In addition, the drug has also shown promising results in reducing tumor growth and metastasis in human lung and colon cancer patients. It also has the ability to enhance the effectiveness of radiation in treating tumors. In addition to its cancer-fighting properties, fenbendazole has a long track record of safety in humans.
While fenbendazole is available as an over-the-counter medication in the United States, it is not approved by Health Canada for use in humans. It is an anthelmintic, and it has been used for decades to treat parasitic worm infestations. However, numerous peer-reviewed articles and research studies have recently been published that show fenbendazole can help to fight multiple types of cancer in humans.
The mechanism by which fenbendazole works is complex. It is believed to bind to the tubulin molecules of cancer cells and disrupt the equilibrium between microtubule formation and depolymerization. This leads to the inhibition of cell division, which in turn causes cellular death. The anthelmintic effect is thought to be enhanced by the interaction of fenbendazole with the microtubules of mammalian cells, which are more prone to polymerization than those in lower organisms.
Despite this complex mechanism of action, fenbendazole has been shown to be an effective treatment for parasitic infections and other conditions in many species. The drug is also known for its anti-tumor properties in a number of cancer types, including large B-cell lymphoma, renal cell carcinoma, and metastatic breast cancer.
In these experiments, mice with EMT6 tumors were injected three times per day with fenbendazole or saline, and then irradiated locally with 10 Gy of x-rays. Tumor volume, body weight, and survival were compared between the control group, mice treated with saline alone, and mice treated with saline plus fenbendazole. Fenbendazole treatment significantly inhibited the growth of EMT6 tumors, and it enhanced the cytotoxicity of x-rays for both the saline and fenbendazole groups. In addition, fenbendazole did not affect the appearance or behavior of the mice during the course of the experiment. The appearance and behavior of mice treated with fenbendazole prior to irradiation were normal. There was no significant difference in the number of local tumor invasion sites or lymph node metastases between the saline and fenbendazole treated groups. This was consistent with a previous report that demonstrated that the combination of fenbendazole and x-rays reduced the spread of paclitaxel-resistant tumors in mice. fenbendazole for humans
ashdev